Matinas BioPharma

Update in progress

MTNB (NYSE American)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company that uses its lipid nanocrystal (LNC) platform to develop medicines. The LNC technology enables delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead candidate, MAT2203, is an oral amphotericin B in Phase 3 for aspergillosis, cryptococcosis, and prevention of invasive fungal infections in immunosuppressed patients. MAT2501 is an oral amikacin. Based in Bedminster, NJ.

Company score

Sentiment: -0.19; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.00; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.35; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.13; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive